SUSPECT ADVERSE REACTION REPORT  I. REACTION INFORMATION  I. PRICE ADVERSE REACTION REPORT  II. REACTION INFORMATION  II. SOUTH NITED AND ADVERSE REACTION REPORT  III. SOUTH NITED AND ADVERSE REACTION REACTION REPORT  III. SOUTH NITED AND ADVERSE REACTION REAC																	C	101	vis_	FO	RM
I. REACTION INFORMATION  1. PAYOR INTINGS  1. COUNTRY  1. CONTAINCA  1. PRIVACY  1. COSTA RICA  1. PRIVACY  2. A 10 EFECURE EXECUTION ONSET  3. A 10 EFECURE EXECUTION ONSET  4. A 10 EFECURE EXECUTION ONSET  3. DAILY SOURCE ON EXECUTION  3. DAILY SOURCE ON																					
I. REACTION INFORMATION  1. PAYOR INTINGS  1. COUNTRY  1. CONTAINCA  1. PRIVACY  1. COSTA RICA  1. PRIVACY  2. A 10 EFECURE EXECUTION ONSET  3. A 10 EFECURE EXECUTION ONSET  4. A 10 EFECURE EXECUTION ONSET  3. DAILY SOURCE ON EXECUTION  3. DAILY SOURCE ON	SHEDE																—				
FAMILIAN DESCRIPTION   Descr	SUSPECT ADVERSE REACTION REPORT									_		_	_					_		_	_
International																					
International							* 4 ^ T ! O N I						1		_						
PRIVACY Privac	1. PATIENT INITIALS									8-1	12	CHE	CK AI	II.			—				
2.11   DREIGNESS REACTION   Contact after (asswer leasted, case)   Contact	(first, last)			Month Year	44			Da	ay	N	/lonth	Ī	Yea	r		APP	ROPR	RIATE		N	
Other Serious Criteria: Medically significant scolosis alterations (Scolosis) Hemorrhoids (Haemorrhoids) Hemorrhoids (Haemorrhoids) Skin altergy (Dermatitis altergic) Influenza symptoms: fever, body aches, moderate to severe general, malaise, runny nose and moderate cough (Pyraxia) Influenza symptoms: fever, body aches, moderate to severe general, malaise, runny nose and moderate cough (Pain)  (Continued on Additional Information Page)  III. SUSPECT DRUG(S) INFORMATION  14. \$USPECT DRUG(S) inFORMATION  14. \$USPECT DRUG(S) inFORMATION  15. DANY DOBES:  #1 ) Abermacicilis (Abermacicilis) Tablet  15. DANY DOBES: #1 ) Formation of Properties and	Todio sas kg sas sa										3										
Scoliosis alterations (Scoliosis) Hemorrhoids (Hamomrhoids) 8 to 9 diarrhea stools daily, some with orange coloration (Faeces discoloured) Skin altery (Diarmatitis allergic) Influenza symptoms: fever, body aches, moderate to severe general, malaise, runny nose and moderate cough (Pyresia) Influenza symptoms: fever, body aches, moderate to severe general, malaise, runny nose and moderate cough (Pain)  (Centinued on Additional Information Page)  II. SUSPECT DRUG(S) INFORMATION  II. SUSPECT DRUG(S) INFORMATION  III. SUSPECT DRUG(S) INFORMATION  II					as)									1		PATII	ENT [	DIED			
Size   Barton Stools daily, some with orange coloration [Facces discoloured]	scoliosis alteratio	ns [Scoliosis]	Alficai	it										1							
Skin allergy (Dermatitis allergic) Influenza symptoms: fever, body aches, moderate to severe general, malaise, runny nose and moderate cough (Pain) (Continued on Additional Information Page) (Continued on Additional Information Page) (Continued on Additional Information Page)  III. SUSPECT DRUG(S) INFORMATION  14. SUSPECT DRUG(S) (Abenacicilis) (Abe		•	h orar	oge coloration [Fa	aeces d	iscoloured]										HUS	PHAL	_ISA i	'ION		
Influenza symptoms: fever, body aches, moderate to severe general, malaise, runny nose and moderate cough (Pyrixia)   (Continued on Additional Information Page)	Skin allergy [Derr	natitis allergic]				•								1		OR S	SIGNII	FICA	.NT	ENT	
Influenza symptoms: fever, body aches, moderate to severe general, malaise, runny nose and moderate cough [Pain]  (Continued on Additional Information Page)  II. SUSPECT DRUG(S) INFORMATION  III. SUSPECT DRUG(S) INFORMATION  III. SUSPECT DRUG(S) INFORMATION  III. DRUG(S) INFORMATION  III. ROUTE(S) OF ADMINISTRATION  III. ROUTE(S) OF ADMINISTRATION  III. ROUTE(S) OF ADMINISTRATION  III. THERAPY DURATION  III. THERAPY DURATION  III. CONCOMITANT DRUG(S) AND HISTORY  III. CONCOMITANT DR		ms: fever, body acr	ies, m	oderate to severe	e genera	al, malaise	, runny nos	se a	nd r	mo	dera	ate			DISABILITY OR						
II. SUSPECT DRUG(S) INFORMATION   The Extension   The Extens	Influenza sympto	ms: fever, body ach	ies, m	oderate to severe	e genera	al, malaise	, runny nos	se a	nd r	mo	dera	ate									
18. BUSPECT DRUGIS) (include genetic name)   20. IDIS REACTION   ABARE AFTER STOPPING   A	Cough [i aiii]					(Conti	nued on Ad	ditio	nal l	nfo	rmat	ion	Page	e)		LIFE	EATE	NINC	·		
18. BUSPECT DRUGIS) (include genetic name)   20. IDIS REACTION   ABARE AFTER STOPPING   A				II. SUSPEC	T DRI	JG(S) IN	FORMA	TIC	N												
#1 ) ADUPODES(S) #1 ) TORMO DID SECTION #1 ) THERAPY DATES(#row/to) #1 ) 23-MAR-2023 / MAY-2025 #1 ) Unknown #1 ) 23-MAR-2023 / MAY-2025 #1 ) Unknown #1 ) Breast cancer (Breast cancer) #1 ) LETROZOLE (LETROZOLE) Unknown; 11-JUL-2023 / Unknown #1 ) LETROZOLE (LETROZOLE) Unknown; 11-JUL-2023 / Unknown #2 ) GOSERELIN (GOSERELIN) Unknown; 11-JUL-2023 / Unknown #2 ) GOSERELIN (GOSERELIN) Unknown; 11-JUL-2023 / Unknown #3 ) Secretary Dates (Breast cancer)  #4 ) WAAUFACTURER INFORMATION #4 ) WAAUFACTURER INFORMATION #4 ) WAAUFACTURER INFORMATION #4 ) WAAUFACTURER INFORMATION #5 ) Secretary Dates (Breast cancer)  #5 ) Secretary Dates (Breast cancer)  #6 ) Secretary Dates (Breast Cancer)  #7 ) Dates (Breast Cance						<i>50</i> (5)			,,,					20					)PPIN		
#1 ) Oral    Tr. NDICATION(S) FOR USE   Tr. NDIC	#1 ) Abemaciclib (A	Abemaciclib) lablet															d		Лінс	٥	
17. INDICATIONS) FOR USE #1   Breast cancer (Breast cancer)  18. THERAPY DURATION #1   23-MAR-2023 / MAY-2025    III. CONCOMITANT DRUG(S) AND HISTORY   19. THERAPY DURATION   19. THER							OF ADMINIST	RATIO	ON					$\dashv$	_	1 <sub>VES</sub>		NO	$\Box$	JΔ	
#1 ) Breast cancer (Breast cancer)    #1 ) Breast cancer (Breast cancer)    #1   Day   Day   Day   Day   Day   Day   Description     #2   DAY   Day   Day   Day   Day   Description     #3   Day   Day   Day   Day   Day   Description     #4   Day   Day   Day   Day   Description     #4   Day   Day   Day   Day   Description     #4   Day   Day   Day   Description     #4   Day   Day   Day   Description     *4   Day   Day   Day   Day   Description     *4   Day   Day   Day   Day   Day   Description     *4   Day   Day   Day   Day   Day   Day   Description     *4   Day   Day   Day   Day   Day   Day   Day   Description     *4   Day   Day	#1 ) 150 mg, biu					#1 ) Olai										]	<u></u>	INC	<u></u>	IA	
18. THERAPY DATES (Iron/Ito)	1													21	RE/	APPE	AR AI	FTER			
#1 ) 23-MAR-2023 / MAY-2025 #1   Unknown	,	<u> </u>												4	KEI	INIK	DUUC	HO	1?		
22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) #1 ) LETROZOLE (LETROZOLE) Unknown; 11-JUL-2023 / Unknown #2 ) GOSERELIN (GOSERELIN) Unknown; 11-JUL-2023 / Unknown #2 ) GOSERELIN (GOSERELIN) Unknown; 11-JUL-2023 / Unknown  23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates Unknown  IV. MANUFACTURER INFORMATION  24a. NAME AND ADDRESS OF MANUFACTURER Eli Lilly Interamerica Inc (AR Branch) Tronador 4890 - Piso 12 Buenos Aires, Capital Federal CP: 1430 ARGENTINA  Phone: 54 1145464000  24b. MFR CONTROL NO. CR202305005630  24c. DATE RECEIVED BY MANUFACTURER 10-JUN-2025  Add REPORT SOURCE STUDY LITERATURE 10-JUN-2025  AME AND ADDRESS WITHHELD. NAME AND ADDRESS WITHHELD.	· ·	·												YES		NO	×	1A			
22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) #1 ) LETROZOLE (LETROZOLE) Unknown; 11-JUL-2023 / Unknown #2 ) GOSERELIN (GOSERELIN) Unknown; 11-JUL-2023 / Unknown #2 ) GOSERELIN (GOSERELIN) Unknown; 11-JUL-2023 / Unknown  23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates Unknown  IV. MANUFACTURER INFORMATION  24a. NAME AND ADDRESS OF MANUFACTURER Eli Lilly Interamerica Inc (AR Branch) Tronador 4890 - Piso 12 Buenos Aires, Capital Federal CP: 1430 ARGENTINA  Phone: 54 1145464000  24b. MFR CONTROL NO. CR202305005630  24c. DATE RECEIVED BY MANUFACTURER 10-JUN-2025  Add REPORT SOURCE STUDY LITERATURE 10-JUN-2025  AME AND ADDRESS WITHHELD. NAME AND ADDRESS WITHHELD.																					
#1) LETROZOLE (LETROZOLE) Unknown; 11-JUL-2023 / Unknown #2) GOSERELIN (GOSERELIN) Unknown; 11-JUL-2023 / Unknown  23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) Type of History / Notes Type of History / Notes Description Medical Condition  IV. MANUFACTURER INFORMATION  24a. NAME AND ADDRESS OF MANUFACTURER Ell Lilly Interamerica Inc (AR Branch) Tronador 4890 - Piso 12 Buenos Aires, Capital Federal CP: 1430 ARGENTINA Phone: 54 1145464000  24b. MFR CONTROL NO. CR202305005630  24c. DATE RECEIVED BY MANUFACTURER 10-JUN-2025  24d. REPORT SOURCE STUDY UTERATURE HEALTH OTHER: NAME AND ADDRESS WITHHELD.						,	) AND H	IST	OF	۲Y											
#2 ) GOSERELIN (GOSERELIN) Unknown; 11-JUL-2023 / Unknown  23. OTHER RELEVANT HISTORY, (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) Type of History / Notes Description Breast cancer (Breast cancer)  IV. MANUFACTURER INFORMATION  24a. NAME AND ADDRESS OF MANUFACTURER Eli Lilly Interamerical inc (AR Branch) Tronador 4890 - Piso 12 Buenos Aires, Capital Federal CP: 1430 ARGENTINA Phone: 54 1145464000  24b. MFR CONTROL NO. CR202305005630  24c. DATE RECEIVED BY MANUFACTURER  24d. RAPPORT SOURCE STUDY UITERATURE HEALTH PROFESSIONAL OTHER: NAME AND ADDRESS WITHHELD.	#1) LETROZOLE	E (LETROZOLE) L	Inknov	wn ; 11-JUL-2023	3 / Unkno	own															
Type of History / Notes Medical Condition  IV. MANUFACTURER INFORMATION  24a. NAME AND ADDRESS OF MANUFACTURER Eli Lilly Interamerica Inc (AR Branch) Tronador 4890 - Piso 12 Buenos Aires, Capital Federal CP: 1430 ARGENTINA Phone: 54 1145464000  24b. MFR CONTROL NO. CR202305005630  24c. DATE RECEIVED BY MANUFACTURER BY MANUFACTURER 10-JUN-2025  24d. REPORT SOURCE STUDY CHERT. DATE OF THIS REPORT 10-JUN-2025  DATE OF THIS REPORT 25a. REPORT TYPE  25a. REPORT TYPE  10-JUN-2025  DATE OF THIS REPORT 25a. REPORT TYPE  25b. NAME AND ADDRESS WITHHELD.																					
Type of History / Notes Medical Condition  IV. MANUFACTURER INFORMATION  24a. NAME AND ADDRESS OF MANUFACTURER Eli Lilly Interamerica Inc (AR Branch) Tronador 4890 - Piso 12 Buenos Aires, Capital Federal CP: 1430 ARGENTINA Phone: 54 1145464000  24b. MFR CONTROL NO. CR202305005630  24c. DATE RECEIVED BY MANUFACTURER BY MANUFACTURER 10-JUN-2025  24d. REPORT SOURCE STUDY LITERATURE HEALTH PROFESSIONAL OTHER: DATE OF THIS REPORT  25a. REPORT TYPE  10-JUN-2025  DATE OF THIS REPORT  25a. REPORT TYPE  25a. REPORT TYPE  10-JUN-2025  DATE OF THIS REPORT  25a. REPORT TYPE  25a. REPORT TYPE																					
Type of History / Notes Medical Condition  IV. MANUFACTURER INFORMATION  24a. NAME AND ADDRESS OF MANUFACTURER Eli Lilly Interamerica Inc (AR Branch) Tronador 4890 - Piso 12 Buenos Aires, Capital Federal CP: 1430 ARGENTINA Phone: 54 1145464000  24b. MFR CONTROL NO. CR202305005630  24c. DATE RECEIVED BY MANUFACTURER BY MANUFACTURER 10-JUN-2025  24d. REPORT SOURCE STUDY CHERT. DATE OF THIS REPORT 10-JUN-2025  DATE OF THIS REPORT 25a. REPORT TYPE  25a. REPORT TYPE  10-JUN-2025  DATE OF THIS REPORT 25a. REPORT TYPE  25b. NAME AND ADDRESS WITHHELD.																					
Unknown    Description		HISTORY. (e.g. diagnostics			onth of perio																
24a. NAME AND ADDRESS OF MANUFACTURER Eli Lilly Interamerica Inc (AR Branch) Tronador 4890 - Piso 12 Buenos Aires, Capital Federal CP: 1430 ARGENTINA Phone: 54 1145464000  24b. MFR CONTROL NO. CR202305005630  24c. DATE RECEIVED BY MANUFACTURER 10-JUN-2025  DATE OF THIS REPORT  25a. REPORT TYPE  26. REMARKS  26. REMARKS  26. REMARKS  26. REMARKS  26. REMARKS  26. REMARKS  27b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.					n	•	ancer (Bre	ast o	cano	cer	)										
24a. NAME AND ADDRESS OF MANUFACTURER Eli Lilly Interamerica Inc (AR Branch) Tronador 4890 - Piso 12 Buenos Aires, Capital Federal CP: 1430 ARGENTINA Phone: 54 1145464000  24b. MFR CONTROL NO. CR202305005630  24c. DATE RECEIVED BY MANUFACTURER 10-JUN-2025  DATE OF THIS REPORT  25a. REPORT TYPE  26. REMARKS  26. REMARKS  26. REMARKS  26. REMARKS  26. REMARKS  26. REMARKS  27b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.																					
24a. NAME AND ADDRESS OF MANUFACTURER Eli Lilly Interamerica Inc (AR Branch) Tronador 4890 - Piso 12 Buenos Aires, Capital Federal CP: 1430 ARGENTINA Phone: 54 1145464000  24b. MFR CONTROL NO. CR202305005630  24c. DATE RECEIVED BY MANUFACTURER 10-JUN-2025  DATE OF THIS REPORT  25a. REPORT TYPE  26. REMARKS  26. REMARKS  26. REMARKS  26. REMARKS  26. REMARKS  26. REMARKS  27b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.																					
24a. NAME AND ADDRESS OF MANUFACTURER Eli Lilly Interamerica Inc (AR Branch) Tronador 4890 - Piso 12 Buenos Aires, Capital Federal CP: 1430 ARGENTINA Phone: 54 1145464000  24b. MFR CONTROL NO. CR202305005630  24c. DATE RECEIVED BY MANUFACTURER 10-JUN-2025  DATE OF THIS REPORT  25a. REPORT TYPE  26. REMARKS  26. REMARKS  26. REMARKS  26. REMARKS  26. REMARKS  26. REMARKS  27b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.																					
Eli Lilly Interamerica Inc (AR Branch) Tronador 4890 - Piso 12 Buenos Aires, Capital Federal CP: 1430 ARGENTINA Phone: 54 1145464000  24b. MFR CONTROL NO. CR202305005630  24c. DATE RECEIVED BY MANUFACTURER 10-JUN-2025  DATE OF THIS REPORT 10-JUN-2025  Eli Lilly Interamerica Inc (AR Branch) Tronador 4890 - Piso 12 BUEN ARGENTINA  25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.	IV. MANUFACTURER INFORMATION																				
Buenos Aires, Capital Federal CP: 1430 ARGENTINA Phone: 54 1145464000  24b. MFR CONTROL NO. CR202305005630  24c. DATE RECEIVED BY MANUFACTURER 10-JUN-2025  24d. REPORT SOURCE STUDY LITERATURE 10-JUN-2025  DATE OF THIS REPORT 25d. REPORT TYPE  25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.	Eli Lilly Interamerio	Eli Lilly Interamerica Inc (AR Branch)																			
24b. MFR CONTROL NO. CR202305005630  24c. DATE RECEIVED BY MANUFACTURER 10-JUN-2025  DATE OF THIS REPORT 25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.	Buenos Aires, Cap	Buenos Aires, Capital Federal CP: 1430 ARGENTINA																			
CR202305005630  NAME AND ADDRESS WITHHELD.	Phone: 54 114546	Phone: 54 1145464000																			
CR202305005630  NAME AND ADDRESS WITHHELD.																					
24c. DATE RECEIVED BY MANUFACTURER  10-JUN-2025  24d. REPORT SOURCE STUDY LITERATURE OTHER: DATE OF THIS REPORT  25a. REPORT TYPE  25a. REPORT TYPE  10-JUN-2025  NAME AND ADDRESS WITHHELD. NAME AND ADDRESS WITHHELD. NAME AND ADDRESS WITHHELD.													_								
24d. REPORT SOURCE  BY MANUFACTURER  10-JUN-2025  DATE OF THIS REPORT  DATE OF THIS REPORT  25a. REPORT TYPE  25d. REPORT SOURCE  DITERATURE  NAME AND ADDRESS WITHHELD.  NAME AND ADDRESS WITHHELD.	CA- DATE BECEIVED																				
10-JUN-2025	BY MANUFACTURER  24d. REPORT SOURCE STUDY  LITERATURE																				
DATE OF THIS REPORT 25a. REPORT TYPE	DDOFFCCIONAL						NAME AND ADDRESS WITHHELD.														
		1_	TYPE	FOLLOWUR:	2																

## **ADDITIONAL INFORMATION**

## 7+13. DESCRIBE REACTION(S) continued

Influenza symptoms: fever, body aches, moderate to severe general, malaise, runny nose and moderate cough [Malaise]
Influenza symptoms: fever, body aches, moderate to severe general, malaise, runny nose and moderate cough [Rhinorrhoea]
Influenza symptoms: fever, body aches, moderate to severe general, malaise, runny nose and moderate cough [Cough]
Change of tonality in the skin of her hips, ankles and arms/ dry skin darker [Skin discolouration]
Diarrhoea]
Low white blood cells [White blood cell count decreased]
Itching [Pruritus]

Case Description: This solicited case reported by a consumer via Patient Support Program (PSP), with additional information from the initial reporter via PSP, concerned a 44-year-old female patient of unknown origin.

Medical history included breast cancer.

The patient received abemaciclib (Verzenio) 150 mg tablet every twelve hours orally for the treatment of breast cancer, beginning on 23-Mar-2023. She received letrozole and goserelin as a concomitant medication for the treatment of unknown indication. On 03-May-2023, after administering abemaciclib therapy, she experienced diarrhea, characterized by four episodes of diarrhea per day and on 06-May-2023, she had five stools of diarrhea. She had the indication to take loperamide two capsules, if necessary, as corrective treatment for diarrhea. On 08-May-2023, eight days after taking abemaciclib therapy, she noticed hemorrhoids; while cleaning herself after defecation, she observed blood on the paper and felt inflammation. Her treating physician indicated that she should use an anti-hemorrhoidal cream for external use three times a day as a corrective treatment. On 12-May-2023, twelve days after taking abemaciclib treatment, she had eight to nine diarrhea stools daily with some orange coloration. On 21-June-2023, approximately one month after taking abemaciclib therapy, the physician indicated that she had low white blood cells (value, unit and reference range was not provided). On 11-Jul-2023, she had three diarrheal stools daily. On 29-Dec-2023 she underwent ovarian surgery, which were removed as a preventive measure, the operation was performed as scheduled and concluded without complications, she was in recovery. Ovarian surgery was scheduled and was performed preventively, not because of any medically relevant findings. On 10-Mar-2024, she developed a skin allergy. She was scheduled to consult with her treating physician on 01-April-2024. On 01-Jun-2024, she had influenza symptoms: fever, body aches, moderate to severe general, malaise, runny nose and moderate cough. On 02-Jun-2024, she had observed a change of tonality in the skin of her hips, ankles and arms, in the form of a belt surrounding those parts of the body. She observed dry skin darker than the rest of the skin, effectively belts that surround the areas for which she took 10% urea cream. Additionally, on same day she experienced itching. She was not hospitalized for skin discoloration and pruritus. On 20-Feb-2025, she referred that bone range and CT scan (computerized tomogram) (Unit, value or reference range was not provided) was performed, which came out with severe scoliosis alterations. There was no metastasis in any part of the body, only severe scoliosis. This would be lifelong condition, and she did not take any medication for the condition. The event of scoliosis was considered as serious by the company due to medically significant reasons. Her therapy was discontinued on an unknown date in May-2025. She took chlorpheniramine maleate as corrective treatment for allergy. Information regarding other corrective treatments was not provided. Outcome of the events was not resolved. Status of abemaciclib therapy was unknown after discontinuation.

The initial reporting consumers did not provide relatedness of the events with abemaciclib therapy.

Update 17-May-2023: Additional information was received on 09-May-2023 (Both the follow ups information received on 09-May-2023 were processed together) from the initial reporter via the PSP. Added one new non-serious event as hemorrhoids. Updated causality statement and narrative with new information.

Update 14-Jul-2023: Additional information was received on 11-Jul-2023, from the initial reporter via the PSP. Added two concomitant medications letrozole and goserelin, one lab test of white blood cell count, and two non-serious events of faeces discolored, and white blood cell count low. Updated the narrative with new information.

Update 26-Jul-2023: Information was received from the initial reporter on 24-Jul-2023. No new medically significant information was reported and hence no new changes were made to the case.

Update 23-Jan-2024: Additional information was received on 16-Jan-2024, from the initial reporter via the PSP. Updated therapy start date to 22-Mar-2023. Updated the narrative with new information.

Update 04-Mar-2024: Upon correction by the local affiliate of the information initially received on 16-Jan-2024, updated report type from spontaneous to post-marketing study, suspect drug coding was updated, as reported causality and as determined causality was updated for all events. Updated the narrative with new information.

Update 23-Mar-2024: Information was received from the initial reporter on 18-Mar-2024. No new medically significant information was reported and hence no new changes were made to the case.

Update 03-Apr-2024: Additional information was received on 28-Mar-2024, from the initial reporter. Added one non-serious event of allergic skin reaction, one treatment drug of chlorphenamine maleate. Information regarding ovarian surgery was added in narrative. Updated the narrative with new information.

## **ADDITIONAL INFORMATION**

## 7+13. DESCRIBE REACTION(S) continued

Update 03-Jun-2024: Information was received from the initial reporter via a PSP on 29-May-2024. No new medically significant information was received. No changes were made to the case.

Update 20-Jun-2024: Additional information was received on 17-Jun-2024, from the initial reporter via PSP. Added five non-serious events of fever, general body pain, malaise, runny nose and cough. Updated the narrative with new information.

Update 24-Aug-2024: Additional information was received on 19-Aug-2024, from the initial reporter via PSP. Added one treatment drug of urea and two non-serious events of skin discoloration and pruritus. Updated the narrative with new information.

Update 10-Sep-2024: Information was received on 04-Sep-2024. No new medically significant information was received and hence no changes were made to the case.

Update 26-Sep-2024: Additional information was received from the initial reporting consumer in response to the follow-up questionnaire on 20-Sep-2024. The patient was not hospitalized for skin discoloration and pruritus. Narrative was updated with new information accordingly.

Update 06-Mar-2025: Additional information was received on 03-Mar-2025, from the initial reporter via PSP and this case had been upgraded to serious due to addition of one serious event scoliosis. Added laboratory test of CT scan (computerized tomogram). Updated start date from 22-Mar-2023 to 23-Mar-2023 and narrative with new information.

Update 06-May-2025: Additional information was received from a reporting consumer via PSP on 30-Apr-2025. Added patient's husband as reporter, severity and onset date for the event of scoliosis, onset date for the events of pruritus, skin discoloration. Updated Treatment Received from unknown to no for the event of scoliosis. Updated the outcome of the events of scoliosis, pruritus, skin discoloration from unknown to not resolved. Updated the narrative with new information received.

Update 13-Jun-2025: Additional information was received from initial reporting consumer via PSP on 10-Jun-2025 and 11-Jun-2025 were processed together. Added stop date of abemaciclib therapy, and patient medical history of breast cancer. Updated status from no change to drug discontinued for abemaciclib therapy, and narrative with new information received.

13	. Lab	Data

#	Date	Test / Assessment / Notes	Results	Normal High / Low
1		Computerised tomogram spine	•	
		Unit, value or reference range	was not provided.	
2	21-JUN-2023	White blood cell count		
		low white blood cells (value, u	nit and reference range v	vas not provided).